inhibitors to increase the amount of acetylcholine present in the synapses between cholinergic neurons3'4).
Acetylcholinesterase inhibitors like tacrine, one of the most extensively evaluated acetylcholinesterase inhibitors, have been shown to significantly improve cognitive function in Alzheimer disease5 '6 All spectra of1 and 2 were recorded at 600 MHzfor !H and 150 MHzfor 13C in CD3C1. aProton resonance multiplicity and coupling constant (J = Hz) are in parenthesis. The assignments were aided by 'H^H COSY, DEPT, NOESY, HMQC,and HMBC.
35.8, q), and one exchangeable proton (5 7.39). Taking into account the molecular formula and the N or 0-linked methyl group, the exchangeable proton should be assigned to be an NH group. In the HMBCspectrum (Fig. 2) , long range couplings were observed from the protons of N-CH3 to the olefinic carbon (C-5) and the sp1 quaternary carbon (C-4a) of the benzene ring and the two sp2 quaternary carbons at 8 110.3 (C-9a) and 8 163.9 (C-3a).
Long range couplings were also observed from the olefinic proton (H-8) of the benzene ring to the carbonyl carbon at 8 173.0 (C-9). This HMBC data suggested the presence of a quinolone moiety. On the other hand, the NHproton at 8 7.39 was long-range coupled to the two sp2 quaternary carbons (C-3a and C-9a). In^H COSYspectrum (Fig. 2) in DMSO-rf6, the NHproton was also coupled to the methine proton (H-3) of 3 CH3-2'CH2~1'CH(CH3)-3CH-group which was, in turn, long-range coupled to the other carbonyl carbon at 8 169.9 (C-l) and the two sp2 quaternary carbons (C-3a and C-9a). These spectral data indicated that a 7-lactam ring containing a sec-butyl group at C-3 is present in its 'H-'HCOSYandHMBCdataof1.
structure and the y-lactam ring should be conjugated at C3a and C-9a of the quinolone moiety. The conjugated pattern of the 7-lactam ring was determined by the NOEsobserved from the protons ofN-CH3 to the protons ofH-5, H-3, and H-l ' (Fig. 3) . Thus the planar structure of 1 was elucidated. The relative stereochemistry of 1 was examined by NOESY spectrum in DMSO-<i6 (Fig. 3 ). NOEs were observed between H-3 and both of H-l' and Ha-2' while no NOEs was observed between H-3 and CH3-1'. NOEswere also observed between the NHand H-3, H2-2', and CH3-1'. These spectral data indicated that the relative stereochemistries of C-3 and C-T were S* and i?*, respectively, with anti configuration of H-3 and CH3-1\ This configuration was also supported by the high fieldshifted chemical shift (5H 0.51, <5C11.4) of CH3-1' which could be induced by anisotrophic effect of the pyrroloquinolone ring. Thus the structure of 1 was determined as shown in Fig. 1 .
The *H and 13C NMRspectra of 2 were very similar to those of 1 ( Table 2 ). The only difference between 1 and 2 in *H and 13C NMRdata with HMQC data was that the methylene of H2-2' and the methyl of H3-3' was upshieldshifted in 2 while the methyl of CH3-1' was down fieldshifted.
The JH NMRspectral data with^H COSYalso revealed the presence of CH3-CH2-CH(CH3)-CH-group like 1. The HMBC spectral data (data not shown) confirmed that the planar structure of 1 was the same as that of 2. Together with CD spectral data, these NMR spectral data indicated that 2 could be a diastereoisomer of 1 . The relative stereochemistry of 2 was examined by NOESY spectrum in DMSO-d6 (Fig. 3 ). NOEs were observed between H-3 and CH3-1' while no NOEswas observed between H-3 and both of H-l' and H2-2'. NOEs were also observed between the proton of NHand H-3 and CH3-1'. These data indicated that the relative THE JOURNAL OF ANTIBIOTICS similar to those of quinolactacin A14), the relative configuration of 2 is assumed to be the same as that of quinolactacin A. Anti-acetylcholinesterase activity of 1 and 2 was evaluated in Ellman's coupled acetylcholinesterse assay15). Interestingly, 2 showed 14-times higher inhibitory activity against acetylcholinesterase than 1. 2 inhibited acetylcholinesterase in a dose-dependent fashion with an IC50 (/xm) value of 19.8 while 1 showed the weak inhibitory activity with an IC50 (/xm) value of280. The inhibition of 2 was competitive with substrate (Fig. 4) 0.12) in this assay system.
